Is there an impact of the number of metastases in the outcome of potentially resectable metastatic colorectal cancer patients receiving bevacizumab...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter J.-P. Metges
Citation Annals of Oncology (2016) 27 (2): 102-117. 10.1093/annonc/mdw200
Authors J.-. Metges1, J. Bennouna2, M. Rivoire3, D. Elias4, F. Bonnetain5, L. Dourthe6, M. Ben Abdelghani7, R. Radji8, P. Laplaige9, F. Petit Laurent10, K. Sébastien11, J. Telliez11, D. Malka4
  • 1C.H.U. Hopital Morvan - Observatory of cancer BPL, Brest, France, /
  • 2Institut de Cancérologie de l'Ouest, Nantes, France, /
  • 3Léon Bérard Cancer Center, Lyon, France, /
  • 4Institut Gustave Roussy, Villejuif, Villejuif, /
  • 5University Hospital of Besançon, Besançon, France, /
  • 6Clinic Strasbourg, Strasbourg, France, /
  • 7Centre Paul Strauss, Strasbourg, France, /
  • 8Centre Frederic Joliot, Rouen, France, /
  • 9Polyclinique de Blois, La Chaussée St Victor, France, /
  • 10Hôpital de Villefranche-sur-Saône, Villefranche-sur-Saône, France, /
  • 11Roche SAS, Boulogne Billancourt, France, /


The PICASSO prospective cohort evaluated patients with no evidence of new metastatic disease (NED) in metastatic colorectal cancer (mCRC) after 1st line bevacizumab-based regimen (BBR) followed or not by secondary metastases resection. The number of metastases in potentially resectable mCRC patients might be considered as a prognostic factor so we conducted this subgroup analysis to describe the outcome of patients with 1 to 3 metastases vs 4 and more (4+).